An update on the long-acting insulin analogue glargine

被引：26
|
作者：
Thisted, Henriette
Johnsen, Soren Paaske
Rungby, Jorgen
机构：
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Endocrinol C, DK-8000 Aarhus C, Denmark
[3] Univ Aarhus, Dept Pharmacol, Aarhus, Denmark
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2006年 / 99卷 / 01期
关键词：
D O I：
10.1111/j.1742-7843.2006.pto_352.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
For both type 1 and type 2 diabetes, tight glycaemic control is vital to reduce the risk of long-term complications. However, this must be achieved with minimal risk of hypoglycaemia. Glargine is a new long-acting insulin analogue with an action profile designed to overcome this and has now been in clinical use for a number of years. In many countries glargine is widely used. Here we present an update on the clinical information available on glargine with respect to glycaemic control, the risk of hypoglycaemia and quality of life in both type 1 and type 2 diabetes.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 50 条
  • [21] Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
    Thorsten Hartmann
    Sabrina Overhagen
    D. Margriet Ouwens
    Silja Raschke
    Paulus Wohlfart
    Norbert Tennagels
    Nina Wronkowitz
    Jürgen Eckel
    Cardiovascular Diabetology, 15
  • [22] Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
    Hartmann, Thorsten
    Overhagen, Sabrina
    Ouwens, D. Margriet
    Raschke, Silja
    Wohlfart, Paulus
    Tennagels, Norbert
    Wronkowitz, Nina
    Eckel, Juergen
    CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [23] Usefulness of the long-acting insulin analogue glargine in basal-bolus therapy for Japanese children and adolescents with type 1 diabetes Mellitus
    Urakami, T.
    Morimoto, S.
    Kubota, S.
    Funaki, S.
    Harada, K.
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2007, 20 (07): : 807 - 815
  • [24] Long-acting insulin analogs
    Rosskamp, RH
    Park, G
    DIABETES CARE, 1999, 22 : B109 - B113
  • [25] Long-acting insulin analogues
    Holt, R
    DIABETES OBESITY & METABOLISM, 2003, 5 (04): : 270 - 270
  • [26] A NEW LONG-ACTING INSULIN
    不详
    BMJ-BRITISH MEDICAL JOURNAL, 1953, 1 (4804): : 266 - 266
  • [27] Economic evaluation of switching type-1 diabetes patients from long-acting insulin glargine in a basal/bolus regimen to long-acting insulin detemir in an Austrian setting
    Palmer, AJ
    Wittrup-Jensen, KU
    Hansen, JB
    Roze, S
    Valentine, WJ
    VALUE IN HEALTH, 2005, 8 (06) : A160 - A160
  • [28] Long-Acting Growth Hormone: An Update
    Saenger, Paul H.
    Mejia-Corletto, Jorge
    ADVANCED THERAPIES IN PEDIATRIC ENDOCRINOLOGY AND DIABETOLOGY, 2016, 30 : 79 - 97
  • [29] Update on long-acting reversible methods
    Conti, Jennifer
    Shaw, Kate
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2015, 27 (06) : 471 - 475
  • [30] Long-acting amylin analogue for weight reduction
    Gadde, Kishore M.
    Allison, David B.
    LANCET, 2021, 398 (10317): : 2132 - 2134
12345